Lipoprotein Metabolism in Obesity and Diabetes: Insights from Stable Isotope Kinetic Studies in Humans

Nutrition Reviews

Volumn 61, Issue 11, 2003, Pages 363-375

  Marsh, Julian B ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

apoA I; apoB 100; apoB 48; Diabetes; HDL; Insulin; Kinetics; LDL; Lipoprotein metabolism; Obesity; Triglyceride; VLDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; TRIACYLGLYCEROL;

BODY MASS; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; ISOTOPE LABELING; KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; OBESITY; REVIEW; WEIGHT REDUCTION;

APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHOLESTEROL, HDL; DIABETES MELLITUS; HUMANS; ISOTOPES; LIPOPROTEINS; OBESITY; TRIGLYCERIDES; WEIGHT LOSS;

EID: 0345255659     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1301/nr.2003.nov.363-375     Document Type: Review

References (104)

1. National Center for Health Statistics, National Vital Statistics System. 2002:Table 32. Available at: http://www.cdc.gov/nchs/nvss.htm. Accessed September 25, 2003.
2. National Health and Nutrition Examination Survey I, II and III. Overweight among U.S. Children and Adolescents. 1999. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed September 25, 2003.
3. National Vital Statistics. Body weight status of adults: United States, 1997-1998; 2002; Report 50, no. 16, Table 70. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed September 25, 2003.
4. National Center for Health Statistics. Healthy weight, overweight, and obesity among persons 20 years of age and over. 2002; Table 70. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed September 25, 2003.
5. National Center for Chronic Disease Prevention and Health Promotion and Diabetes Surveillance System. Prevalence of diabetes. 2003. Available at: http://www.cdc.gov/nchs/. Accessed September 25, 2003.
6. Barrett PHR, Watts, GF. Kinetic studies of lipoprotein metabolism, in the metabolic syndrome including effects of nutritional interventions. Curr Opin Lipidol. 2003;14:61-68.
7. Reaven G. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88:2399-2403.
8. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrinol Rev. 2001;21:697-738
9. Kelner K, Helmuth L. Obesity - what is to be done? Science. 2003;299:845.
10. Moro E, Gallina P, Pais N, Cazzolato G, Alessandrini P, Bittolo-Bon G. Hypertriglyceridemia is associated with increased insulin resistance in subjects with normal glucose tolerance: evaluation in a large cohort of subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes. Metabolism. 2003;52:616-619.
11. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999;1A:28J-32J.
12. Lamon-Fava S, Wilson PWF, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women: The Framingham Off-spring Study. Arterioscler Thromb Vasc Biol. 1996;16:1509-1515.
13. Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med. 1993;153:1040-1103.
14. Friedland O, Nemet D, Wolach B, Eliakim A. Obesity and lipid profiles in children and adolescents. J Pediatr Endocrinol Metab. 2002;15:1011-1016.
15. Tershakovec AM, Jawad AF, Stouffer NO, Elkasabany A, Srinivasan SR, Berenson GS. Persistent hypercholesterolemia is associated with the development of obesity among girls: the Bogalusa Heart Study. Am J Clin Nutr. 2002;76:730-735.
16. Nieves DJ, Cnop M, Retzlaff B, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003;52:172-179.
17. Sasahara T, Yamashita T, Sviridov D, Fidge N, Nestel P. Altered properties of high density lipoprotein subfractions in obese subjects. J Lipid Res. 1997;38:600-611.
18. James RW, Brulhart-Meynet MC, Lehmann T, Golay A. Lipoprotein distribution and composition in obesity: their association with central adiposity. Int J Obes. 1997;21:1115-1120.
19. Abbott WGH, Lillioja S, Young AA, et al. Relationship between lipoprotein concentration and insulin action in an obese hyperinsulinemic population. Diabetes. 1987;36:897-904.
20. Berman DM, Rogus EM, Busby-Whitehead MJ, Katzel LI, Goldberg AP. Predictors of adipose tissue lipoprotein lipase in middle-aged and older men: relationship to leptin and obesity, but not cardiovascular fitness. Metabolism. 1999;2:183-189.
21. Jeppesen J, Hollenbeck CB, Zhou MY, et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol. 1995;15:320-324.
22. Cominacini L, Garbin U, Davoli A, et al. High-density lipoprotein cholesterol concentrations and postheparin hepatic and lipoprotein lipases in obesity: relationships with plasma insulin levels. Ann Nutr Metab. 1993;37:175-184.
23. Rönnemaa T, Marniemi J, Savolainen MJ, et al. Serum lipids, lipoproteins, and lipid metabolizing enzymes in identical twins discordant for obesity. J Clin Endocrinol Metab. 1998;8:2792-2799.
24. Cummings MH, Watts GF, Pal C, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin Sci. 1995;88:225-233.
25. Mittendorfer B, Patterson BW, Klein S. Effect of sex and obesity on basal VLDL-triacylglycerol kinetics. Am J Clin Nutr. 2003;77:573-579.
26. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes. 1998;22:414-423.
27. Volk A, Renn W, Overkamp D, et al. Insulin action and secretion in healthy, glucose tolerant first degree relatives of patients with type 2 diabetes mellitus. Influence of body weight. Exp Clin Endocrinol Diabetes. 1999;2:140-147.
28. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metab Clin Exper. 2002;51:1041-1046.
29. Watts GF, Chan DC, Barrett PH. Adipose tissue compartments and the kinetics of very-low-density lipoprotein apolipoprotein B-100 in non-obese men. Metabolism. 2002;51:1206-1210.
30. Aalto-Setälä K, Fisher EA, Chen X., et al. Mechanism of hypertriglyceridemia in human apolipoprotein (Apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased Apo CIII and reduced Apo E on the particles. J Clin Invest. 1992;90:1889-1900.
31. Sumner AE, Falkner B, Diffenderfer MR, Barrett PHR, Marsh JB. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males. Proc Soc Exp Biol Med. 1999;4:352-360.
32. Jingami H, Yamamoto T. The VLDL receptor: wayward brother of the LDL receptor. Curr Opin Lipidol. 1995;6:104-108.
33. Pont F, Duvillard L, Florentin E, Gambert P, Verges B. Early kinetic abnormalities of ApoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol. 2002;22:1726-1732.
34. Mittendorfer B, Sidossis LS. Mechanism for the increase in plasma triacylglycerol concentrations after consumption of short-term, high-carbohydrate diets. Am J Clin Nutr. 2001;5:892-899.
35. Mittendorfer B, Patterson BW, Klein S, Sidossis LS. VLDL-triglyceride kinetics during hyperglycemia-hyperinsulinemia: effects of sex and obesity. Am J Physiol Endocrinol Metab. 2003;284:E708-E715.
36. Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab. 2000;5:E1003-E1011.
37. Sumner AE, Kushner H, Sherif KD, Tulenko TN, Falkner B, Marsh JB. Sex differences in African-Americans regarding sensitivity to insulin's glucoregulatory and antilipolytic actions. Diabetes Care. 1999;22:71-77.
38. Faraj M, Jones P, Sniderman AD, Enhanced dietary fat clearance in postobese women. J Lipid Res. 2001;4:571-580.
39. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999;8:2854-2861.
40. Mittendorfer B, Patterson BW, Klein S. Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity. Am J Physiol Endocrinol Metab. 2003;284:E549-E556.
41. Wilson MA, Vega GL, Gylling H, Grundy SM. Persistence of abnormalities in metabolism of apolipoproteins B-100 and A-I after weight reduction in patients with primary hypertriglyceridemia. Arterioscler Thromb. 1992;12:976-984.
42. Bergman RN, Van Atters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. J Invest Med. 2001;49:119-126.
43. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293-300.
44. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes. 2002;51:2929-2935.
45. Eisenstein J, Greenberg A. Ghrelin: update 2003. Nutr Rev. 2003;61:101-104.
46. Talmud PJ, Hawe E, Martin S, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11:3039-3046.
47. Vega GL, Grundy SM. Influence of Iovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med. 1991;230:341-350.
48. Cuchel M, Schaefer EJ, Millar JS, et al. Lovastatin decreases de novo cholesterol synthesis and LDL apo B-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol. 1997;17:1910-1917.
49. Huff, MW, Burnett JR. 3-Hydroxy-3-methyglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol. 1997;8:138-145.
50. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Scahefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis. 2002;162:227-244.
51. Williams KJ, Brocia RW, Fisher EA. The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem. 1990;265:16741-16744.
52. Chan, DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab. 2002;87:2283-2289.
53. Vajo Z, Terry JG, Brinton EA. Increased intraabdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in post-menopausal women. Atherosclerosis. 2002;160:495-501.
54. Pont, F, Duvillard L, Florentin E, Gambert P, Verges B. High-density lipoprotein A-I kinetics in obese insulin-resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord. 2002;26:1151-1158.
55. 3] leucine in middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol. 2000;3:801-806.
56. Cowie CC, Howard BV, Harris MI. Serum lipoproteins in African Americans and whites with noninsulin-dependent diabetes in the US population. Circulation. 1994;90:1185-1193.
57. Siegel RD, Cupples A, Schaefer EJ, Wilson PWF. Lipoproteins, apolipoproteins, and low density lipoproteins particle size among diabetics in the Framingham Offspring Study. Metabolism. 1996;45:1267-1272.
58. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis-the atherosclerosis and insulin resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000;20:2140-2147.
59. Lemieux I, Pascot A, Lamarche B, et al. Is the gender difference in LDL size explained by the metabolic complications of visceral obesity? Eur J Clin Invest. 2002;32:909-917.
60. Christ ER, Carroll PV, Albany E, et al. Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;282:E1154-E1162.
61. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res. 2002;43:177-186.
62. Nikkila EA, Kekki M. Plasma triglyceride transport kinetics in diabetes mellitus. Metabolism. 1973;22:1-23.
63. Howard BV, Abbott WG, Beltz WF, et al. Integrated study of low-density lipoprotein metabolism and very-low-density lipoprotein metabolism in noninsulin-dependent diabetes. Metabolism. 1987;36:870-877.
64. Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of VLDL apoB100 in NIDDM. Diabetologia. 1995;38:959-967.
65. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in noninsulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000;8:685-694.
66. Millar JS, Lichtenstein AH, Cuchel M, et al. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res. 1995;36:1155-1167.
67. Cummings MH, Watts GF, Umpleby AM, et al. Acute hyperinsulinemia decreases the hepatic secretion of VLDL apoB100 in NIDDM. Diabetes. 1995;44:1059-1065.
68. Huang YD, Ji ZS, Brecht WJ, Rall SC Jr, Taylor JM, Mahley RW. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol. 1999;12:2952-2959.
69. Bach-Ngohou K, Ougerram K, Nazih H, et al. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes. Int J Obes Relat Metab Disord. 2002;26:1451-1458.
70. Millar JS, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Proposal of a multicompartmental model for use in the study of apolipoprotein E metabolism. Metabolism. 1998;8:922-928.
71. Millar JS, Lichtenstein AH, Ordovas JM, Dolnikowski GG, Schaefer EJ. Human triglyceride-rich lipoprotein apo E kinetics and its relationship to LDL apoB-100 metabolism. Atherosclerosis. 2001;155:477-486.
72. Verges B. Apolipoprotein A-IV in diabetes mellitus. Diabetes Metab. 1995;21:99-105.
73. Sun Z, Lichtenstein AH, Dolnikoski GG, Welty FK, Schaefer EJ. Human apolipoprotein A-IV metabolism within triglyceride-rich lipoproteins and plasma. Atherosclerosis. 2001;156:363-372.
74. Batal R, Tremblay M, Barrett PHR, et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2000;41:706-718.
75. Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurements of HDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987;65:512-518.
76. Frenais R, Ougerram K, Maugeais C, et al. High density lipoprotein apolipoprotein Al kinetics in NIDDM: a stable isotope study. Diabetologia. 1997;40:578-583.
77. Duvillard L, Pont F, Florentin E, Gambert P, Verges B. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in NIDDM. Atherosclerosis. 2000;152:229-237.
78. Frenais R, Ougerram K, Maugeais C, et al. High density lipoprotein apolipoprotein Al kinetics in NIDDM: a stable isotope study. Diabetologia. 1997;40:578-583.
79. Frenais R, Nazzih H, Ougerram R, et al. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein Al metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab. 2001;86:962-967.
80. Christ ER, Carroll PV, Albany E, et al. Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol. 2001;55:777-787.
81. Christ ER, Carroll PV, Albany E, et al. Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;282:E1154-E1162.
82. Taskinen MR, Kahri J, Koivisto V, Shepherd J, Packard CJ. Metabolism of HDL apolipoprotein A-I and A-II in Type I (insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:347-356.
83. Harris WS, Muzio F. Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates. Am J Clin Nutr. 1993;58:68-74.
84. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989;30:785-807.
85. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr. 2000;71:202S-207S.
86. Nestel PJ. Effects of n-3 fatty acids on lipid metabolism. Annu Rev Nutr. 1990;10:149-167.
87. Wang H, Chen X, Fisher EA. n-3 Fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. J Clin Invest. 1993;91:1380-1389.
88. Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol. 2000;11:3-7.
89. Chan DC, Watts GF, Mori TA, Barrett PHR, Redgrave TG, Beilin LJ. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300-307.
90. Fisher WR, Zech LA, Stacpoole PW. Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched diet. J Lipid Res. 1998;39:388-401.
91. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002;51:2377-2386.
92. Frenais R, Ougerram K, Maugeais C, et al. Effect of dietary omega-3 fatty acids on high-density lipoprotein A-I kinetics in type II diabetes mellitus. Atherosclerosis. 2001;157:131-135.
93. Barrett PHR, Watts GF. HDL kinetics, fish oils and diabetes. Atherosclerosis. 2001;159:243-244.
94. Boden G, Chen XH, Capulong E, Mazzoli M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes. 2001;4:810-816.
95. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes. 2001;50:1612-1617.
96. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med. 2002;80:753-769.
97. Carey DGP. Abdominal obesity. Curr Opin Lipidol. 1998;9:35-40.
98. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459-481.
99. Edwards P, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res. 2002;43:2-12.
100. Zammit VA, Waterman IJ, Topping, D, McKay G. Insulin stimulation of hepatic triacylglycerol secretion and the etiology of insulin resistance. J Nutr. 2001;131:2074-2077.
101. Cohen P, Miyazaki M, Socci ND, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 2002;297:240-243.
102. Ntambi J, Miyazaki M. Recent insights into stearoyl-CoA desaturase. Curr Opin Lipidol. 2003;14:255-261.
103. Marsh JB, Diffenderfer MR. Isolation of nascent high-density lipoprotein from rat liver perfusates by immunoaffinity chromatography: effects of oleic acid infusion. Metabolism. 1991;40:26-30.
104. Oram JF, Lawn RM. ABCA1: the gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001;42:1173-1179.